398 related articles for article (PubMed ID: 16243442)
1. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
2. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
5. Concurrent paclitaxel and radiation therapy for breast cancer.
Formenti SC; Symmans WF; Volm M; Skinner K; Cohen D; Spicer D; Danenberg PV
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):34-42. PubMed ID: 10210538
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvant combined radiochemotherapy: a feasibility study of a new strategy in stages I and II].
Serin D; Aimard L; Kirscher S; Brewer Y; Félix-Faure C; Vincent P; Chauvet B; Reboul F
Bull Cancer; 1997 Mar; 84(3):247-53. PubMed ID: 9207869
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Han S; Kim J; Sohn S; Kwak GH; Kim JY; Park K
J Surg Oncol; 2007 Jan; 95(1):45-50. PubMed ID: 17192866
[TBL] [Abstract][Full Text] [Related]
9. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
[TBL] [Abstract][Full Text] [Related]
10. [Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].
Tsutani Y; Saeki T; Aogi K; Ohsumi S; Takashima S
Gan To Kagaku Ryoho; 2005 Jun; 32(6):809-13. PubMed ID: 15984521
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML; Berry DA; Cirrincione C; Hudis C; Winer EP; Gradishar WJ; Davidson NE; Martino S; Livingston R; Ingle JN; Perez EA; Carpenter J; Hurd D; Holland JF; Smith BL; Sartor CI; Leung EH; Abrams J; Schilsky RL; Muss HB; Norton L
J Clin Oncol; 2003 Apr; 21(8):1431-9. PubMed ID: 12668651
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
15. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
[TBL] [Abstract][Full Text] [Related]
19. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
